{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:41:39Z","timestamp":1794559299448,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8064","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,5,22]]},"DOI":"10.1038\/s41586-025-08845-y","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:03:16Z","timestamp":1744801396000},"page":"978-983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":179,"title":["Phase I trial of hES\u00a0cell-derived dopaminergic neurons for Parkinson\u2019s disease"],"prefix":"10.1038","volume":"641","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-1670","authenticated-orcid":false,"given":"V.","family":"Tabar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sarva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-0180","authenticated-orcid":false,"given":"A.","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2394-4990","authenticated-orcid":false,"given":"K. K. H.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8383-6748","authenticated-orcid":false,"given":"Y.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-636X","authenticated-orcid":false,"given":"S.","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-864X","authenticated-orcid":false,"given":"D.","family":"Eidelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tomishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Irion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Stemple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lampron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0741-7987","authenticated-orcid":false,"given":"L.","family":"Studer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Henchcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"8845_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"75","author":"ER Dorsey","year":"2018","unstructured":"Dorsey, E. R. & Bloem, B. R. The Parkinson pandemic\u2014a call to action. JAMA Neurol. 75, 9\u201310 (2018).","journal-title":"JAMA Neurol."},{"key":"8845_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris, H. R., Spillantini, M. G., Sue, C. M. & Williams-Gray, C. H. The pathogenesis of Parkinson\u2019s disease. Lancet 403, 293\u2013304 (2024).","journal-title":"Lancet"},{"key":"8845_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong, M. J. & Okun, M. S. Diagnosis and treatment of Parkinson disease: a review. JAMA 323, 548\u2013560 (2020).","journal-title":"JAMA"},{"key":"8845_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Primers 3, 17013 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"8845_CR5","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.3390\/jcm12072573","volume":"12","author":"KG Heimrich","year":"2023","unstructured":"Heimrich, K. G., Sch\u00f6nenberg, A., Santos-Garc\u00eda, D., Mir, P., Coppadis Study Group & Prell, T. The impact of nonmotor symptoms on health-related quality of life in Parkinson\u2019s disease: a network analysis approach. J. Clin. Med. 12, 2573 (2023).","journal-title":"J. Clin. Med."},{"key":"8845_CR6","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1212\/WNL.0b013e3181f6128c","volume":"75","author":"KA Chung","year":"2010","unstructured":"Chung, K. A., Lobb, B. M., Nutt, J. G. & Horak, F. B. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 75, 1263\u20131269 (2010).","journal-title":"Neurology"},{"key":"8845_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","volume":"15","author":"EJ Henderson","year":"2016","unstructured":"Henderson, E. J. et al. Rivastigmine for gait stability in patients with Parkinson\u2019s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 15, 249\u2013258 (2016).","journal-title":"Lancet Neurol."},{"key":"8845_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","volume":"23","author":"RA Hauser","year":"2000","unstructured":"Hauser, R. A. et al. A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia. Clin. Neuropharmacol. 23, 75\u201381 (2000).","journal-title":"Clin. Neuropharmacol."},{"key":"8845_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/jnnp-2022-329192","volume":"94","author":"NI Kremer","year":"2023","unstructured":"Kremer, N. I. et al. STN-DBS electrode placement accuracy and motor improvement in Parkinson\u2019s disease: systematic review and individual patient meta-analysis. J. Neurol. Neurosurg. Psychiatry 94, 236\u2013244 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"8845_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2202721","volume":"388","author":"V Krishna","year":"2023","unstructured":"Krishna, V. et al. Trial of globus pallidus focused ultrasound ablation in Parkinson\u2019s disease. N. Engl. J. Med. 388, 683\u2013693 (2023).","journal-title":"N. Engl. J. Med."},{"key":"8845_CR11","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/jamaneurol.2017.3098","volume":"74","author":"AE Bond","year":"2017","unstructured":"Bond, A. E. et al. Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial. JAMA Neurol. 74, 1412\u20131418 (2017).","journal-title":"JAMA Neurol."},{"key":"8845_CR12","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang, A. E. et al. Trial of cinpanemab in early Parkinson\u2019s disease. N. Engl. J. Med. 387, 408\u2013420 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8845_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano, G. et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N. Engl. J. Med. 387, 421\u2013432 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8845_CR14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMe2401743","volume":"390","author":"DG Standaert","year":"2024","unstructured":"Standaert, D. G. GLP-1, Parkinson\u2019s disease, and neuroprotection. N. Engl. J. Med. 390, 1233\u20131234 (2024).","journal-title":"N. Engl. J. Med."},{"key":"8845_CR15","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner, W. G. et al. Trial of lixisenatide in early Parkinson\u2019s disease. N. Engl. J. Med. 390, 1176\u20131185 (2024).","journal-title":"N. Engl. J. Med."},{"key":"8845_CR16","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.3233\/JPD-212739","volume":"11","author":"A Abeliovich","year":"2021","unstructured":"Abeliovich, A., Hefti, F. & Sevigny, J. Gene therapy for Parkinson\u2019s disease associated with GBA1 mutations. J. Parkinsons Dis. 11, S183\u2013S188 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"8845_CR17","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.3233\/JPD-212724","volume":"11","author":"AD Van Laar","year":"2021","unstructured":"Van Laar, A. D. et al. An update on gene therapy approaches for Parkinson\u2019s disease: restoration of dopaminergic function. J. Parkinsons Dis. 11, S173\u2013S182 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"8845_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1474-4422(20)30036-3","volume":"19","author":"RMA de Bie","year":"2020","unstructured":"de Bie, R. M. A., Clarke, C. E., Espay, A. J., Fox, S. H. & Lang, A. E. Initiation of pharmacological therapy in Parkinson\u2019s disease: when, why, and how. Lancet Neurol. 19, 452\u2013461 (2020).","journal-title":"Lancet Neurol."},{"key":"8845_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/ana.410420115","volume":"42","author":"GK Wenning","year":"1997","unstructured":"Wenning, G. K. et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson\u2019s disease. Ann. Neurol. 42, 95\u2013107 (1997).","journal-title":"Ann. Neurol."},{"key":"8845_CR20","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1056\/NEJM199211263272202","volume":"327","author":"CR Freed","year":"1992","unstructured":"Freed, C. R. et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson\u2019s disease. N. Engl. J. Med. 327, 1549\u20131555 (1992).","journal-title":"N. Engl. J. Med."},{"key":"8845_CR21","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/brain\/123.7.1380","volume":"123","author":"P Brundin","year":"2000","unstructured":"Brundin, P. et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson\u2019s disease. Brain 123, 1380\u20131390 (2000).","journal-title":"Brain"},{"key":"8845_CR22","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/brain\/122.6.1121","volume":"122","author":"P Hagell","year":"1999","unstructured":"Hagell, P. et al. Sequential bilateral transplantation in Parkinson\u2019s disease: effects of the second graft. Brain 122, 1121\u20131132 (1999).","journal-title":"Brain"},{"key":"8845_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ana.410350208","volume":"35","author":"O Lindvall","year":"1994","unstructured":"Lindvall, O. et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson\u2019s disease. Ann. Neurol. 35, 172\u2013180 (1994).","journal-title":"Ann. Neurol."},{"key":"8845_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/brain\/117.3.487","volume":"117","author":"M Peschanski","year":"1994","unstructured":"Peschanski, M. et al. Bilateral motor improvement and alteration of l-dopa effect in two patients with Parkinson\u2019s disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117, 487\u2013499 (1994).","journal-title":"Brain"},{"key":"8845_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.10720","volume":"54","author":"CW Olanow","year":"2003","unstructured":"Olanow, C. W. et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease. Ann. Neurol. 54, 403\u2013414 (2003).","journal-title":"Ann. Neurol."},{"key":"8845_CR26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJM200103083441002","volume":"344","author":"CR Freed","year":"2001","unstructured":"Freed, C. R. et al. Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease. N. Engl. J. Med. 344, 710\u2013719 (2001).","journal-title":"N. Engl. J. Med."},{"key":"8845_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003391","volume":"4","author":"M Politis","year":"2012","unstructured":"Politis, M. et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson\u2019s patients treated with dopamine grafts. Sci. Transl. Med. 4, 128ra141 (2012).","journal-title":"Sci. Transl. Med."},{"key":"8845_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamaneurol.2013.4749","volume":"71","author":"Z Kefalopoulou","year":"2014","unstructured":"Kefalopoulou, Z. et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 71, 83\u201387 (2014).","journal-title":"JAMA Neurol"},{"key":"8845_CR29","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.celrep.2014.05.027","volume":"7","author":"PJ Hallett","year":"2014","unstructured":"Hallett, P. J. et al. Long-term health of dopaminergic neuron transplants in Parkinson\u2019s disease patients. Cell Rep. 7, 1755\u20131761 (2014).","journal-title":"Cell Rep."},{"key":"8845_CR30","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.1073\/pnas.1605245113","volume":"113","author":"W Li","year":"2016","unstructured":"Li, W. et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc. Natl Acad. Sci. USA 113, 6544\u20136549 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8845_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10648","volume":"480","author":"S Kriks","year":"2011","unstructured":"Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson\u2019s disease. Nature 480, 547\u2013551 (2011).","journal-title":"Nature"},{"key":"8845_CR32","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3124","volume":"33","author":"JA Steinbeck","year":"2015","unstructured":"Steinbeck, J. A. et al. Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson\u2019s disease model. Nat. Biotechnol. 33, 204\u2013209 (2015).","journal-title":"Nat. Biotechnol."},{"key":"8845_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.stem.2021.01.005","volume":"28","author":"TW Kim","year":"2021","unstructured":"Kim, T. W. et al. Biphasic activation of WNT signaling facilitates the derivation of midbrain dopamine neurons from hESCs for translational use. Cell Stem Cell 28, 343\u2013355 (2021).","journal-title":"Cell Stem Cell"},{"key":"8845_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.stem.2021.01.004","volume":"28","author":"J Piao","year":"2021","unstructured":"Piao, J. et al. Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01. Cell Stem Cell 28, 217\u2013229 (2021).","journal-title":"Cell Stem Cell"},{"key":"8845_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00401-008-0352-8","volume":"115","author":"G Rudow","year":"2008","unstructured":"Rudow, G. et al. Morphometry of the human substantia nigra in ageing and Parkinson\u2019s disease. Acta Neuropathol. 115, 461\u2013470 (2008).","journal-title":"Acta Neuropathol."},{"key":"8845_CR36","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/jnen\/60.8.741","volume":"60","author":"P Hagell","year":"2001","unstructured":"Hagell, P. & Brundin, P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J. Neuropathol. Exp. Neurol. 60, 741\u2013752 (2001).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"8845_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mds.21198","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov. Disord. 22, 41\u201347 (2007).","journal-title":"Mov. Disord."},{"key":"8845_CR38","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/phar.2718","volume":"42","author":"J Nelson","year":"2022","unstructured":"Nelson, J. et al. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and International Society for Heart and Lung Transplantation: an executive summary. Pharmacotherapy 42, 594\u2013598 (2022).","journal-title":"Pharmacotherapy"},{"key":"8845_CR39","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/TP.0000000000001651","volume":"101","author":"JM Neuberger","year":"2017","unstructured":"Neuberger, J. M. et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 101, S1\u2013S56 (2017).","journal-title":"Transplantation"},{"key":"8845_CR40","unstructured":"Martinez\u2013Martin, P., Rodriguez-Blazquez, C. & Forjaz, M. J. in Neuroscience and Biobehavioral Psychology 8\u201316 (Elsevier, 2017)."},{"key":"8845_CR41","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/archneurol.2009.295","volume":"67","author":"LM Shulman","year":"2010","unstructured":"Shulman, L. M. et al. The clinically important difference on the unified Parkinson\u2019s disease rating scale. Arch. Neurol. 67, 64\u201370 (2010).","journal-title":"Arch. Neurol."},{"key":"8845_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2967\/jnumed.109.066811","volume":"51","author":"Y Ma","year":"2010","unstructured":"Ma, Y. et al. Dopamine cell implantation in Parkinson\u2019s disease: long-term clinical and 18F-FDOPA PET outcomes. J. Nucl. Med. 51, 7\u201315 (2010).","journal-title":"J. Nucl. Med."},{"key":"8845_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"JY Li","year":"2008","unstructured":"Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat. Med. 14, 501\u2013503 (2008).","journal-title":"Nat. Med."},{"key":"8845_CR44","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat. Med. 14, 504\u2013506 (2008).","journal-title":"Nat. Med."},{"key":"8845_CR45","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41591-019-0507-2","volume":"25","author":"RA Barker","year":"2019","unstructured":"Barker, R. A. Designing stem-cell-based dopamine cell replacement trials for Parkinson\u2019s disease. Nat. Med. 25, 1045\u20131053 (2019).","journal-title":"Nat. Med."},{"key":"8845_CR46","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","volume":"382","author":"JS Schweitzer","year":"2020","unstructured":"Schweitzer, J. S. et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson\u2019s disease. N. Engl. J. Med. 382, 1926\u20131932 (2020).","journal-title":"N. Engl. J. Med."},{"key":"8845_CR47","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.stem.2023.08.014","volume":"30","author":"A Kirkeby","year":"2023","unstructured":"Kirkeby, A. et al. Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson\u2019s disease, STEM-PD. Cell Stem Cell 30, 1299\u20131314 (2023).","journal-title":"Cell Stem Cell"},{"key":"8845_CR48","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.neuroimage.2011.02.046","volume":"56","author":"B Patenaude","year":"2011","unstructured":"Patenaude, B., Smith, S. M., Kennedy, D. N. & Jenkinson, M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 56, 907\u2013922 (2011).","journal-title":"Neuroimage"},{"key":"8845_CR49","first-page":"1324","volume":"43","author":"V Dhawan","year":"2002","unstructured":"Dhawan, V. et al. Comparative analysis of striatal FDOPA uptake in Parkinson\u2019s disease: ratio method versus graphical approach. J. Nucl. Med. 43, 1324\u20131330 (2002).","journal-title":"J. Nucl. Med."},{"key":"8845_CR50","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2967\/jnumed.108.061572","volume":"50","author":"P Jokinen","year":"2009","unstructured":"Jokinen, P. et al. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J. Nucl. Med. 50, 893\u2013899 (2009).","journal-title":"J. Nucl. Med."},{"key":"8845_CR51","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.1075","volume":"50","author":"T Nakamura","year":"2001","unstructured":"Nakamura, T. et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson\u2019s disease. Ann. Neurol. 50, 181\u2013187 (2001).","journal-title":"Ann. Neurol."},{"key":"8845_CR52","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ana.10359","volume":"52","author":"Y Ma","year":"2002","unstructured":"Ma, Y. et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann. Neurol. 52, 628\u2013634 (2002).","journal-title":"Ann. Neurol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08845-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08845-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08845-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T03:06:04Z","timestamp":1747883164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08845-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":52,"journal-issue":{"issue":"8064","published-print":{"date-parts":[[2025,5,22]]}},"alternative-id":["8845"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-08845-y","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.T. is a scientific advisor and receives research support from BlueRock Therapeutics. H.S. has done consulting work for Novo Nordisk, BlueRock Therapeutics, Neurocrine and Neuroderm; and has also received clinical trial support from BlueRock Therapeutics, Prevail Therapeutics, Neuroderm, Sun Pharma, Meira GTX, Bukwang, Insightec, Biogen, Genentech, Cerevance, UCB and National Institutes of Health (NIH). A.M.L. has done consulting work for Medtronic, Abbott, Boston Scientific and Insightec; and is a scientific officer of Functional Neuromodulation. A.F. has stock ownership in Inbrain Pharma and has received payments as consultant and\/or speaker from AbbVie, Abbott, Boston Scientific, CereGate, Domp\u00e9 Farmaceutici, Inbrain Neuroelectronics, Ipsen, Medtronic, Iota, Syneos Health, Merz, Sunovion, Paladin Labs and UCB; and has received research support from AbbVie, BlueRock Therapeutics, Boston Scientific, Medtronic, Praxis and ES, and receives royalties from Springer. S.K.K. has received consultant fees, support and\/or speaker honoraria from Novo Nordisk, Abbott, Boston Scientific and Medtronic. Y.M. has served as a consultant, study investigator and site principal investigator to acquire and\/or analyse PET\/SPECT and MRI brain images in multicentre clinical trials of stem cell and gene therapies for PD; and has received research support and paid travel from BlueRock Therapeutics and Aspen Neuroscience, research support from AskBio and MeiraGTx, and paid consulting services from Novo Nordisk. S.I., M.T., N.A. and W.S. are employees of BlueRock Therapeutics. A.L. is currently an employee of Domp\u00e9. L.S. is a scientific advisor and receives research support from BlueRock Therapeutics and is a scientific co-founder of DaCapo Brainscience. C.H. has received honoraria for consulting from Abbvie, AskBio and Certara; stock options for scientific advisory board participation from Axent Biosciences; honoraria for scientific advisory board participation from Bayer, Canary Health Technologies and ProJenX; honoraria for DSMB meetings from MeiraGTx; research support from BlueRock Therapeutics and Weston Brain Institute; and honoraria for presentations from the American Academy of Neurology, ASGCT and the Parkinson Study Group. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}